Our study demonstrated significant therapeutic efficacy of our UTMC platform compared to that of other reports using different STAT3 decoy delivery platforms and higher STAT3 decoy doses in HNSCC models. This evidence concerns the gene STAT3 and head and neck squamous cell carcinoma.